SecBot SecBot
PRESS-RELEASE ·Filed May 22, 2026

IOVA

Iovance Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Routine new-hire equity grant, no trading signal. Monitor upcoming quarterly results for commercial progress on Amtagvi and pipeline updates.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.10
T+0 close · May 22, 2026 · via day close
Latest settled
+94.88%
T+60 · $7.99
Vs SPY
+92.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $4.10entry
  2. T+1 · 6mo ago +8.05%α +8.09% · $4.43
  3. T+5 · 6mo ago −3.41%α −4.50% · $3.96
  4. T+20 · 5mo ago +5.87%α +7.81% · $4.34
  5. T+60 · 3mo ago +94.88%α +92.15% · $7.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics granted inducement stock options covering 93,340 shares to 13 new non-executive employees under its 2021 Inducement Plan. The options have an exercise price of $3.70 and vest over three years. This is a routine equity grant for new hires, not a material financial event.

Key Facts

  • 93,340 shares of common stock granted as inducement stock options to 13 new non-executive employees.
  • Exercise price of $3.70, equal to the closing price on the grant date (May 21, 2026).
  • Options vest over three years: one-third on first anniversary, remainder in quarterly installments.
  • Granted under the Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).

Financial Impact

93,340 shares at $3.70 per share = approximately $345,000 in potential option value; immaterial relative to Iovance's $1.7B market cap.

dilution

Risk Factors

  • No material risk from this grant; dilution is negligible.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
76% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3300384

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 22, 2026